Arctic Bioscience Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Christer Valderhaug

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	6.2yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

CEO

Christer Valderhaug (52 yo)

no data

Tenure

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Harald Nordal	Co-Founder & Chairman	9.1yrs	geen gegevens	0.079% € 3.3k
Christer Valderhaug	Chief Executive Officer	no data	geen gegevens	0.055% € 2.3k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.6yrs	geen gegevens	1.83% € 77.8k
Jone Slinning	Chief Financial Officer	2.6yrs	geen gegevens	0.052% € 2.2k
Per Sæbo	Chief Operating Officer	12.3yrs	geen gegevens	0.090% € 3.8k
Daniele Mancinelli	Chief Technical Officer	12.3yrs	geen gegevens	0.0079% € 334.4
Steffen Eidal	Senior Vice President of Sales & Marketing	2.6yrs	geen gegevens	geen gegevens
Yuming Feng	Executive Vice President of Global Business Development	6.2yrs	geen gegevens	geen gegevens
Runhild Gammelsæter	Global Medical Director	5.3yrs	geen gegevens	0.14% € 5.8k

6.2yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 9TD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Harald Nordal	Co-Founder & Chairman	9.1yrs	geen gegevens	0.079% € 3.3k
Jostein Dalland	Independent Board Member	4.7yrs	geen gegevens	geen gegevens
Tore Andreas Tonseth	Board Member	3.8yrs	geen gegevens	geen gegevens
Asbjorn Solevagseide	Board Member	5.6yrs	geen gegevens	geen gegevens
Jan Vartdal	Board Member	9.1yrs	geen gegevens	4.1% € 174.0k
Per Eggesbo	Board Member	8.8yrs	geen gegevens	geen gegevens
Hu Cao	Board Member	3.8yrs	geen gegevens	geen gegevens
Marita Holstad	Director	3.8yrs	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 9TD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Arctic Bioscience Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Recent updates

Arctic Bioscience AS Provides Revenue Guidance for the Year 2024

New major risk - Market cap size

Arctic Bioscience Announces Top-Line Results from Phase 2b HeROPA Study

New major risk - Financial position

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings released: kr1.79 loss per share (vs kr1.39 loss in FY 2022)

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings released

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd